Novo Nordisk A/S/€NOVOB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.
Ticker
€NOVOB
Sector
Primary listing
XGAT
Employees
78,554
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk A/S Metrics
BasicAdvanced
€234B
16.71
€3.12
0.35
€1.56
2.99%
Price and volume
Market cap
€234B
Beta
0.35
52-week high
€90.53
52-week low
€35.76
Average daily volume
740K
Dividend rate
€1.56
Financial strength
Current ratio
0.776
Quick ratio
0.533
Long term debt to equity
52.491
Total debt to equity
59.574
Dividend payout ratio (TTM)
49.88%
Interest coverage (TTM)
19.21%
Profitability
EBITDA (TTM)
22,161.168
Gross margin (TTM)
83.44%
Net profit margin (TTM)
32.88%
Operating margin (TTM)
48.69%
Effective tax rate (TTM)
21.33%
Revenue per employee (TTM)
€538,310
Management effectiveness
Return on assets (TTM)
21.11%
Return on equity (TTM)
71.46%
Valuation
Price to earnings (TTM)
16.71
Price to revenue (TTM)
5.491
Price to book
10.3
Price to tangible book (TTM)
27.65
Price to free cash flow (TTM)
28.434
Free cash flow yield (TTM)
3.52%
Free cash flow per share (TTM)
1.836
Dividend yield (TTM)
2.99%
Growth
Revenue change (TTM)
16.64%
Earnings per share change (TTM)
10.06%
3-year revenue growth (CAGR)
23.59%
10-year revenue growth (CAGR)
11.78%
3-year earnings per share growth (CAGR)
26.29%
10-year earnings per share growth (CAGR)
13.82%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk A/S stock?
Novo Nordisk A/S (NOVOB) has a market cap of €234B as of January 28, 2026.
What is the P/E ratio for Novo Nordisk A/S stock?
The price to earnings (P/E) ratio for Novo Nordisk A/S (NOVOB) stock is 16.71 as of January 28, 2026.
Does Novo Nordisk A/S stock pay dividends?
Yes, the Novo Nordisk A/S (NOVOB) stock pays dividends to shareholders. As of January 28, 2026, the dividend rate is €1.56116 and the yield is 2.99%. Novo Nordisk A/S has a payout ratio of 49.88% on a trailing twelve-month basis.
When is the next Novo Nordisk A/S dividend payment date?
The next Novo Nordisk A/S (NOVOB) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk A/S?
Novo Nordisk A/S (NOVOB) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.